Nomura restated their buy rating on shares of Voyager Therapeutics (NASDAQ:VYGR) in a research note published on Tuesday morning, AnalystRatings.com reports. Nomura currently has a $37.00 target price on the stock.
“Minor Tweaks Post-NBIX Collab., Revising Patient Numbers and Statistical Plan; No Data Guidance Yet. The first pivotal Parkinson’s disease trial, RESTORE-1, is undergoing minor modifications now that VYGR is partnered with NBIX. VYGR had previously guided to a 75-100 patient trial, but this is likely going to be clarified as the statistical analysis plan is finalized. No data guidance yet—but we expect an update when the target enrollment is finalized and when VYGR gets a sense of the pace of enrollment. Huntington’s Program IND by YE19 – Finalizing Clinical Team and Planning to Use Commercial-Grade Gene Therapy Material. Voyager recently attained full rights after the SNY collaboration restructuring (see our note here). VYGR plans to have an IND by YE19 and will use material that is “very, very similar” to commercial material to avoid any step back in the future.”,” Nomura’s analyst wrote.
A number of other analysts also recently issued reports on the company. BidaskClub downgraded Voyager Therapeutics from a hold rating to a sell rating in a research report on Wednesday, August 7th. HC Wainwright reissued a buy rating and set a $26.00 price objective on shares of Voyager Therapeutics in a research report on Monday. Wedbush raised their target price on Voyager Therapeutics from $27.00 to $36.00 and gave the company an outperform rating in a report on Tuesday, June 18th. Finally, Morgan Stanley raised their target price on Voyager Therapeutics from $21.00 to $28.00 and gave the company an equal weight rating in a report on Friday, July 12th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of Buy and a consensus price target of $27.50.
Shares of NASDAQ:VYGR opened at $20.62 on Tuesday. The business has a 50-day moving average price of $24.00 and a 200 day moving average price of $20.68. The company has a market capitalization of $791.41 million, a price-to-earnings ratio of -7.50 and a beta of 2.55. Voyager Therapeutics has a 12-month low of $7.76 and a 12-month high of $28.79.
Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings data on Friday, August 9th. The company reported $0.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.88) by $1.17. The firm had revenue of $46.09 million during the quarter, compared to the consensus estimate of $5.25 million. Voyager Therapeutics had a negative return on equity of 82.98% and a negative net margin of 106.23%. On average, sell-side analysts expect that Voyager Therapeutics will post -2.67 EPS for the current year.
Institutional investors have recently made changes to their positions in the stock. Steward Partners Investment Advisory LLC purchased a new position in Voyager Therapeutics during the 2nd quarter valued at about $27,000. NumerixS Investment Technologies Inc purchased a new position in Voyager Therapeutics during the 2nd quarter valued at about $30,000. SG3 Management LLC purchased a new position in Voyager Therapeutics during the 1st quarter valued at about $57,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Voyager Therapeutics by 371.4% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,126 shares of the company’s stock valued at $58,000 after acquiring an additional 1,675 shares during the period. Finally, Bank of Montreal Can boosted its holdings in Voyager Therapeutics by 244.1% during the 2nd quarter. Bank of Montreal Can now owns 2,811 shares of the company’s stock valued at $76,000 after acquiring an additional 1,994 shares during the period. Institutional investors own 73.92% of the company’s stock.
About Voyager Therapeutics
Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease.
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.